Articles on Patented medicine prices review board

Displaying all articles

New guidelines for the Patented Medicine Prices Review Board are set to take effect Jan. 1, 2026. THE CANADIAN PRESS/Ryan Remiorz

Canada’s new drug pricing guidelines are industry‑friendly

Joel Lexchin, York University, Canada

The Patented Medicine Prices Review Board’s mandate is to make sure that drug prices are not excessive. However, new guidelines that change criteria for assessing prices may lead to higher prices.
Canadians pay high drug prices, but the pharmaceutical industry claims it is a ‘key partner in economic resilience, recovery and growth.’ (Shutterstock)

High drug prices in Canada are just one side of a bad equation

Sandra Sirrs, University of British Columbia and Joel Lexchin, University of Toronto; York University, Canada; University of Sydney

Canadians pay very high drug costs, but Canada also does not receive the same economic benefits from pharmaceutical industry investments as other countries do.
Changes to the Patented Medicine Prices Review Board regulations, which are intended to help lower drug costs in Canada, were originally scheduled to take effect in July 2020. (Shutterstock)

Lower drug prices are a priority for Canadians, but not for the federal government

Joel Lexchin, University of Toronto; York University, Canada; University of Sydney

Changes to Canada’s Patented Medicine Prices Review Board regulations have been postponed for a fourth time in two years as Canadians continue to pay some of the highest drug prices in the world.

Related Topics

  1. Big Pharma
  2. Drug manufacturing
  3. Drug prices
  4. Drugs
  5. Economy
  6. Investment
  7. Pharmacare
  8. Pharmaceuticals
  9. Prescription drug prices

Top contributors